Search
Search Our Medical Library
Shionogi Medical offers access to clinical and educational resources across Shionogi’s portfolio. Search the library to find the information you need.
The content contained in these documents are for your information only. No reproduction, alteration, or distribution of this information is permitted. Information about investigational compounds or investigational uses of products does not imply FDA approval of these compounds or uses, nor does it establish the safety or efficacy of these compounds or uses. There is no guarantee that the investigational compounds or investigational uses will receive FDA approval. Shionogi does not recommend or suggest use of its products in a manner inconsistent with FDA-approved labeling. Healthcare providers are responsible for individual patient care on the basis of their professional knowledge and experience.
A randomized phase 2/3 study of ensitrelvir, a novel oral SARS-CoV-2 3C-like protease inhibitor, in Japanese patients with mild-to-moderate COVID-19 or asymptomatic SARS-CoV-2 infection: Results of the phase 2a part
A randomized phase 2/3 study of ensitrelvir, a novel oral SARS-CoV-2 3C-like protease inhibitor, in Japanese patients with mild-to-moderate COVID-19 or asymptomatic SARS-CoV-2 infection: Results of the phase 2a part
Drug-drug interaction of cefiderocol, a siderophore cephalosporin, via human drug transporters
Drug-drug interaction of cefiderocol, a siderophore cephalosporin, via human drug transporters
Ensitrelvir for the prevention of COVID-19 among household contacts: Key subgroup analyses of SCORPIO-PEP phase 3 study
Ensitrelvir for the prevention of COVID-19 among household contacts: Key subgroup analyses of SCORPIO-PEP phase 3 study
Ensitrelvir in hospitalized patients with SARS-CoV-2 during the Omicron epidemic: A single-center observational study
Ensitrelvir in hospitalized patients with SARS-CoV-2 during the Omicron epidemic: A single-center observational study
Phenotyping and genotyping analysis using baseline swab samples in ensitrelvir clinical studies
Phenotyping and genotyping analysis using baseline swab samples in ensitrelvir clinical studies
In vitro potency of ceftibuten with xeruborbactam against β-lactamase-producing isolates of Enterobacterales (ENT) from the SENTRY global surveillance programme
In vitro potency of ceftibuten with xeruborbactam against β-lactamase-producing isolates of Enterobacterales (ENT) from the SENTRY global surveillance programme
Cefiderocol treatment in patients with Gram-negative bacterial infections: European results of the global retrospective observational PROVE study
Cefiderocol treatment in patients with Gram-negative bacterial infections: European results of the global retrospective observational PROVE study
Activity of cefiderocol against clinical isolates of Pseudomonas aeruginosa collected from five European countries as part of the
SENTRY antimicrobial surveillance programme 2020–2023
Activity of cefiderocol against clinical isolates of Pseudomonas aeruginosa collected from five European countries as part of the
SENTRY antimicrobial surveillance programme 2020–2023
Activity of cefiderocol against clinical isolates of Acinetobacter baumannii complex collected from five European countries as part of
the SENTRY antimicrobial surveillance programme 2020–2023
Activity of cefiderocol against clinical isolates of Acinetobacter baumannii complex collected from five European countries as part of
the SENTRY antimicrobial surveillance programme 2020–2023
Activity of cefiderocol against clinical isolates of Stenotrophomonas maltophilia collected from five European countries as part of the
SENTRY antimicrobial surveillance programme 2020–2023
Activity of cefiderocol against clinical isolates of Stenotrophomonas maltophilia collected from five European countries as part of the
SENTRY antimicrobial surveillance programme 2020–2023
Activity of cefiderocol against carbapenem-resistant Pseudomonas aeruginosa, including molecularly characterized clinical isolates, causing infections in hospitals in European and adjacent regions (2020–2023)
Activity of cefiderocol against carbapenem-resistant Pseudomonas aeruginosa, including molecularly characterized clinical isolates, causing infections in hospitals in European and adjacent regions (2020–2023)
In vitro activity of cefiderocol, a siderophore cephalosporin, against a recent collection of clinically relevant carbapenem-non-susceptible Gram-negative bacilli, including serine carbapenemase- and metallo-β-lactamase-producing isolates (SIDERO-WT-2014 study)
In vitro activity of cefiderocol, a siderophore cephalosporin, against a recent collection of clinically relevant carbapenem-non-susceptible Gram-negative bacilli, including serine carbapenemase- and metallo-β-lactamase-producing isolates (SIDERO-WT-2014 study)
Activity of cefiderocol against carbapenem-resistant and molecularly characterized Enterobacterales isolates causing infections in hospitals in Europe and adjacent regions (2020–2023)
Activity of cefiderocol against carbapenem-resistant and molecularly characterized Enterobacterales isolates causing infections in hospitals in Europe and adjacent regions (2020–2023)
Activity of cefiderocol against carbapenem-resistant Acinetobacter baumannii-calcoaceticus complex, including molecularly characterized clinical isolates, causing infections in hospitals in European and adjacent regions (2020–2023)
Activity of cefiderocol against carbapenem-resistant Acinetobacter baumannii-calcoaceticus complex, including molecularly characterized clinical isolates, causing infections in hospitals in European and adjacent regions (2020–2023)
Activity of cefiderocol against metallo-β-lactamase-carrying Enterobacterales, stratified by allele, collected as part of the SENTRY antimicrobial surveillance program
Activity of cefiderocol against metallo-β-lactamase-carrying Enterobacterales, stratified by allele, collected as part of the SENTRY antimicrobial surveillance program
Activity of cefiderocol against Enterobacterales carrying multiple carbapenemases, collected as part of the SENTRY antimicrobial surveillance program
Activity of cefiderocol against Enterobacterales carrying multiple carbapenemases, collected as part of the SENTRY antimicrobial surveillance program
Cefiderocol activity against resistant bacteria from patients with ventilator-associated pneumonia from European and US hospitals
Cefiderocol activity against resistant bacteria from patients with ventilator-associated pneumonia from European and US hospitals
Ensitrelvir treatment–emergent amino acid substitutions in SARS-CoV-2 3CLpro detected in the SCORPIO-SR phase 3 trial
Ensitrelvir treatment–emergent amino acid substitutions in SARS-CoV-2 3CLpro detected in the SCORPIO-SR phase 3 trial
Population pharmacokinetics of ensitrelvir in healthy participants and participants with SARS-CoV-2 infection in the SCORPIO-SR study
Population pharmacokinetics of ensitrelvir in healthy participants and participants with SARS-CoV-2 infection in the SCORPIO-SR study
Effectiveness and safety of cefiderocol treatment in patients with Gram-negative bacterial infections in Spain in the early access programme: results of the PERSEUS study
Effectiveness and safety of cefiderocol treatment in patients with Gram-negative bacterial infections in Spain in the early access programme: results of the PERSEUS study
Cefiderocol treatment for patients infected by Stenotrophomonas maltophilia, Burkholderia cepacia complex and Achromobacter spp.: subgroup analysis from the PERSEUS study
Cefiderocol treatment for patients infected by Stenotrophomonas maltophilia, Burkholderia cepacia complex and Achromobacter spp.: subgroup analysis from the PERSEUS study
In vitro activity of cefiderocol, a siderophore cephalosporin, against Gram-Negative bacilli isolated by clinical laboratories in North America and Europe in 2015-2016: SIDERO-WT-2015
In vitro activity of cefiderocol, a siderophore cephalosporin, against Gram-Negative bacilli isolated by clinical laboratories in North America and Europe in 2015-2016: SIDERO-WT-2015
Comparison of conventional and iron-depleted agar plates for susceptibility testing of cefiderocol by disk diffusion
Comparison of conventional and iron-depleted agar plates for susceptibility testing of cefiderocol by disk diffusion
Ensitrelvir in hospitalized patients with SARS-CoV-2 during the Omicron epidemic: A single-center observational study
Ensitrelvir in hospitalized patients with SARS-CoV-2 during the Omicron epidemic: A single-center observational study
Effect of cefiderocol, a siderophore cephalosporin, on QT/QTc interval in healthy adult subjects
Effect of cefiderocol, a siderophore cephalosporin, on QT/QTc interval in healthy adult subjects
The impact of commercially available media on cefiderocol susceptibility testing by broth microdilution method (Supplemental Video: Determination of cefiderocol MIC values using the broth microdilution method)
The impact of commercially available media on cefiderocol susceptibility testing by broth microdilution method (Supplemental Video: Determination of cefiderocol MIC values using the broth microdilution method)
The impact of commercially available media on cefiderocol susceptibility testing by broth microdilution method (Supplemental Video: Preparation of iron-depleted cation-adjusted Mueller–Hinton broth)
The impact of commercially available media on cefiderocol susceptibility testing by broth microdilution method (Supplemental Video: Preparation of iron-depleted cation-adjusted Mueller–Hinton broth)
The impact of commercially available media on cefiderocol susceptibility testing by broth microdilution method (Supplemental Figure: Summary of the preparation of the iron-depleted cation-adjusted Mueller–Hinton broth)
The impact of commercially available media on cefiderocol susceptibility testing by broth microdilution method (Supplemental Figure: Summary of the preparation of the iron-depleted cation-adjusted Mueller–Hinton broth)
The impact of commercially available media on cefiderocol susceptibility testing by broth microdilution method
The impact of commercially available media on cefiderocol susceptibility testing by broth microdilution method
Ensitrelvir (ESV) population pharmacokinetics (PK) in nonhospitalized adults with COVID-19
Ensitrelvir (ESV) population pharmacokinetics (PK) in nonhospitalized adults with COVID-19
Reduced susceptibility mechanism to cefiderocol, a siderophore cephalosporin, among clinical isolates from a global surveillance programme (SIDERO-WT-2014)
Reduced susceptibility mechanism to cefiderocol, a siderophore cephalosporin, among clinical isolates from a global surveillance programme (SIDERO-WT-2014)
Clearance of infectious virus in COVID-19 patients treated with ensitrelvir across vaccination status, age, and risk subgroups: exploratory analyses from the SCORPIO-HR study
Clearance of infectious virus in COVID-19 patients treated with ensitrelvir across vaccination status, age, and risk subgroups: exploratory analyses from the SCORPIO-HR study
Activity of cefiderocol and comparator agents against carbapenem-resistant Enterobacterales, including molecularly characterized isolates recovered from United States hospitals in 2020–2024
Activity of cefiderocol and comparator agents against carbapenem-resistant Enterobacterales, including molecularly characterized isolates recovered from United States hospitals in 2020–2024
In vitro activity of cefiderocol against resistant subsets of Pseudomonas aeruginosa collected from United States hospitals during 2020–2024
In vitro activity of cefiderocol against resistant subsets of Pseudomonas aeruginosa collected from United States hospitals during 2020–2024
In vitro activity of cefiderocol against carbapenem-nonsusceptible Acinetobacter baumannii-calcoaceticus complex, including molecularly characterized clinical isolates, causing infections in United States hospitals (2020–2024)
In vitro activity of cefiderocol against carbapenem-nonsusceptible Acinetobacter baumannii-calcoaceticus complex, including molecularly characterized clinical isolates, causing infections in United States hospitals (2020–2024)
β-lactam–β-lactamase inhibitor combinations show a high degree of cross-resistance in gram-negative bacteria, but not to cefiderocol results from the SENTRY antimicrobial surveillance program (2020–2024)
β-lactam–β-lactamase inhibitor combinations show a high degree of cross-resistance in gram-negative bacteria, but not to cefiderocol results from the SENTRY antimicrobial surveillance program (2020–2024)
In vitro activity of cefiderocol against clinical strains collected from China in 2023
In vitro activity of cefiderocol against clinical strains collected from China in 2023
Population pharmacokinetic/pharmacodynamic analysis of cefiderocol in Chinese patients with complicated urinary tract infections
Population pharmacokinetic/pharmacodynamic analysis of cefiderocol in Chinese patients with complicated urinary tract infections
Analyzing trends of cefiderocol susceptibility across five years of the SENTRY surveillance program
Analyzing trends of cefiderocol susceptibility across five years of the SENTRY surveillance program
Pharmacodynamic assessment of combination of cefiderocol with xeruborbactam in murine thigh infection model
Pharmacodynamic assessment of combination of cefiderocol with xeruborbactam in murine thigh infection model
In vitro activity of cefiderocol and comparators against isolates of Gram-negative pathogens from a range of infection sources: SIDERO-WT-2014-2018 studies in Italy
In vitro activity of cefiderocol and comparators against isolates of Gram-negative pathogens from a range of infection sources: SIDERO-WT-2014-2018 studies in Italy
Inner zones of inhibition in disk diffusion testing of cefiderocol best reflect activity against Acinetobacter baumannii
Inner zones of inhibition in disk diffusion testing of cefiderocol best reflect activity against Acinetobacter baumannii
Earlier cefiderocol use was associated with better outcomes for challenging gram-negative bacterial infections: US results from the global observational PROVE study
Earlier cefiderocol use was associated with better outcomes for challenging gram-negative bacterial infections: US results from the global observational PROVE study
Clinical outcomes of cefiderocol for treatment of bloodstream infections caused by gram-negative bacteria: subgroup analysis of the PROVE study
Clinical outcomes of cefiderocol for treatment of bloodstream infections caused by gram-negative bacteria: subgroup analysis of the PROVE study
Cefiderocol remains active against US clinical isolates of Stenotrophomonas maltophilia non-susceptible to comparator agents: results from the SENTRY antimicrobial surveillance program (2020–2024)
Cefiderocol remains active against US clinical isolates of Stenotrophomonas maltophilia non-susceptible to comparator agents: results from the SENTRY antimicrobial surveillance program (2020–2024)
Outcomes of patients treated with cefiderocol for infections caused by β-lactam–β-lactamase inhibitor non-susceptible bacteria: subgroup analysis of the PROVE study
Outcomes of patients treated with cefiderocol for infections caused by β-lactam–β-lactamase inhibitor non-susceptible bacteria: subgroup analysis of the PROVE study
Activity of cefiderocol and comparator agents against metallo-β-lactamase carrying Acinetobacter baumannii-calcoaceticus complex isolates collected in the SENTRY antimicrobial surveillance program
Activity of cefiderocol and comparator agents against metallo-β-lactamase carrying Acinetobacter baumannii-calcoaceticus complex isolates collected in the SENTRY antimicrobial surveillance program
Real-world impact of early outpatient COVID-19 antiviral treatment on post-COVID-19 condition: the ANCHOR-01 study
Real-world impact of early outpatient COVID-19 antiviral treatment on post-COVID-19 condition: the ANCHOR-01 study
In vitro activity of cefiderocol and comparators against isolates of Gram-negative bacterial pathogens from a range of infection sources: SIDERO-WT-2014-2018 studies in Spain
In vitro activity of cefiderocol and comparators against isolates of Gram-negative bacterial pathogens from a range of infection sources: SIDERO-WT-2014-2018 studies in Spain
Cefiderocol treatment for gram-negative bacterial infections in patients with cystic fibrosis: results from the multinational observational PROVE study
Cefiderocol treatment for gram-negative bacterial infections in patients with cystic fibrosis: results from the multinational observational PROVE study
Activity of cefiderocol against Pseudomonas aeruginosa from the USA and Europe (2020-2023) with difficult-to-treat resistance phenotype, including those nonsusceptible to recently developed β-lactam/β-lactamase inhibitor combinations: results from the SENTRY antimicrobial surveillance program
Activity of cefiderocol against Pseudomonas aeruginosa from the USA and Europe (2020-2023) with difficult-to-treat resistance phenotype, including those nonsusceptible to recently developed β-lactam/β-lactamase inhibitor combinations: results from the SENTRY antimicrobial surveillance program
Carbapenem-resistant Acinetobacter spp infection in critically ill patients with limited treatment options: a descriptive study of cefiderocol therapy during the COVID-19 pandemic
Carbapenem-resistant Acinetobacter spp infection in critically ill patients with limited treatment options: a descriptive study of cefiderocol therapy during the COVID-19 pandemic
Iron serum levels and iron homeostasis parameters in patients with nosocomial pneumonia treated with cefiderocol: post hoc analysis of the APEKS-NP study
Iron serum levels and iron homeostasis parameters in patients with nosocomial pneumonia treated with cefiderocol: post hoc analysis of the APEKS-NP study
Impact of oral antiviral therapy on subsequent hospital visits and antibacterial use in COVID-19 outpatients within 28 days
Impact of oral antiviral therapy on subsequent hospital visits and antibacterial use in COVID-19 outpatients within 28 days
Mechanisms of reduced susceptibility to cefiderocol among isolates from the CREDIBLE-CR and APEKS-NP clinical trials
Mechanisms of reduced susceptibility to cefiderocol among isolates from the CREDIBLE-CR and APEKS-NP clinical trials
Understanding mechanisms of reduced cefiderocol susceptibility in pvdS and fecI mutants of Pseudomonas aeruginosa
Understanding mechanisms of reduced cefiderocol susceptibility in pvdS and fecI mutants of Pseudomonas aeruginosa
S-337395, a novel L-protein inhibitor of respiratory syncytial virus demonstrates dose-dependent antiviral activity in a human challenge study
S-337395, a novel L-protein inhibitor of respiratory syncytial virus demonstrates dose-dependent antiviral activity in a human challenge study
Outcomes with cefiderocol treatment in patients with bacteraemia enrolled into prospective Phase 2 and Phase 3 randomised clinical studies
Outcomes with cefiderocol treatment in patients with bacteraemia enrolled into prospective Phase 2 and Phase 3 randomised clinical studies
Antimicrobial snapshot: cefiderocol
Antimicrobial snapshot: cefiderocol
Effects of ensitrelvir on the pharmacokinetics of combined oral contraceptives (ethinyl estradiol/drospirenone) in healthy adult women: a phase 1 fixed-sequence, multiple-dose, drug–drug interaction study
Effects of ensitrelvir on the pharmacokinetics of combined oral contraceptives (ethinyl estradiol/drospirenone) in healthy adult women: a phase 1 fixed-sequence, multiple-dose, drug–drug interaction study
Cefiderocol treatment in polymicrobial infections: subgroup analysis of the real-world PROVE observational study
Cefiderocol treatment in polymicrobial infections: subgroup analysis of the real-world PROVE observational study
Real-world cefiderocol outcomes in the treatment of Stenotrophomonas spp. infections: data from the PROVE study
Real-world cefiderocol outcomes in the treatment of Stenotrophomonas spp. infections: data from the PROVE study
Cefiderocol in clinical practice for bone and joint infections: insights from the PROVE study
Cefiderocol in clinical practice for bone and joint infections: insights from the PROVE study
In vitro activity of cefiderocol and comparators against Gram-negative bacterial isolates from a series of surveillance studies in England: 2014-2018
In vitro activity of cefiderocol and comparators against Gram-negative bacterial isolates from a series of surveillance studies in England: 2014-2018
Efficacy and safety of cefiderocol or colistin in a randomised, open-label phase 3 study in Chinese participants with carbapenem-resistant gram-negative bacterial infections
Efficacy and safety of cefiderocol or colistin in a randomised, open-label phase 3 study in Chinese participants with carbapenem-resistant gram-negative bacterial infections
Real-world efficacy of cefiderocol for treatment of infections caused by metallo-beta-lactamase-producing enterobacterales in Spain
Real-world efficacy of cefiderocol for treatment of infections caused by metallo-beta-lactamase-producing enterobacterales in Spain
Categorisation of routine cefiderocol susceptibility by EUCAST zone diameter breakpoints has low predictability of clinical outcome for metallo-beta-lactamase-producing Enterobacterales
Categorisation of routine cefiderocol susceptibility by EUCAST zone diameter breakpoints has low predictability of clinical outcome for metallo-beta-lactamase-producing Enterobacterales
Pharmacokinetics, safety and tolerability of cefiderocol in paediatric patients aged 3 months to <18 years with suspected or confirmed gram-negative bacterial infections: results of the phase 1b–2 APEKS-PEDI study
Pharmacokinetics, safety and tolerability of cefiderocol in paediatric patients aged 3 months to <18 years with suspected or confirmed gram-negative bacterial infections: results of the phase 1b–2 APEKS-PEDI study
Activity of cefiderocol against Stenotrophomonas maltophilia clinical isolates collected in multi-national antimicrobial surveillance studies SIDERO-WT (2014–2019) and SENTRY (2020–2024)
Activity of cefiderocol against Stenotrophomonas maltophilia clinical isolates collected in multi-national antimicrobial surveillance studies SIDERO-WT (2014–2019) and SENTRY (2020–2024)
Activity of cefiderocol against resistant isolates collected from bloodstream infections during 2020 to 2024 as part of the SENTRY antimicrobial surveillance program
Activity of cefiderocol against resistant isolates collected from bloodstream infections during 2020 to 2024 as part of the SENTRY antimicrobial surveillance program
Activity of cefiderocol and comparator agents against European enterobacterales, including carbapenem-resistant isolates, from the SENTRY antimicrobial surveillance program (2020–2024)
Activity of cefiderocol and comparator agents against European enterobacterales, including carbapenem-resistant isolates, from the SENTRY antimicrobial surveillance program (2020–2024)
Activity of cefiderocol against non-fermenting gram-negative isolates collected from intensive care unit patients in US and European medical centers as part of the SENTRY antimicrobial surveillance program (2020–2024)
Activity of cefiderocol against non-fermenting gram-negative isolates collected from intensive care unit patients in US and European medical centers as part of the SENTRY antimicrobial surveillance program (2020–2024)
Cefiderocol demonstrated potent in vitro activity against carbapenem-resistant non-fermenting gram-negative bacteria, including WHO priority pathogens, in China
Cefiderocol demonstrated potent in vitro activity against carbapenem-resistant non-fermenting gram-negative bacteria, including WHO priority pathogens, in China
Ensitrelvir treatment of COVID-19 across multiple global phase 3 trials resulted in reduced culture positivity and RNA copy number with minimal viral rebound
Ensitrelvir treatment of COVID-19 across multiple global phase 3 trials resulted in reduced culture positivity and RNA copy number with minimal viral rebound
Pharmacokinetics, pharmacodynamics, and dose optimization of cefiderocol during continuous renal replacement therapy
Pharmacokinetics, pharmacodynamics, and dose optimization of cefiderocol during continuous renal replacement therapy
Safety, tolerability, and pharmacokinetics of secutrelvir: single and multiple oral doses, and drug-drug interaction with midazolam
Safety, tolerability, and pharmacokinetics of secutrelvir: single and multiple oral doses, and drug-drug interaction with midazolam
Phase 2 study of secutrelvir, a second-generation 3C-like protease inhibitor as oral treatment for COVID-19
Phase 2 study of secutrelvir, a second-generation 3C-like protease inhibitor as oral treatment for COVID-19
Population pharmacokinetic/ pharmacodynamic analyses of cefiderocol for paediatric patients
Population pharmacokinetic/ pharmacodynamic analyses of cefiderocol for paediatric patients
Exploratory post hoc analysis of neutrophil-to-lymphocyte ratio as a novel responsiveness biomarker for edaravone oral suspension-treated patients with amyotrophic lateral sclerosis vs untreated propensity score-matched PRO-ACT historical placebo controls
Exploratory post hoc analysis of neutrophil-to-lymphocyte ratio as a novel responsiveness biomarker for edaravone oral suspension-treated patients with amyotrophic lateral sclerosis vs untreated propensity score-matched PRO-ACT historical placebo controls
Intrapulmonary pharmacokinetic modeling and simulation of cefiderocol, a parenteral siderophore cephalosporin, in patients with pneumonia and healthy subjects
Intrapulmonary pharmacokinetic modeling and simulation of cefiderocol, a parenteral siderophore cephalosporin, in patients with pneumonia and healthy subjects
Ensitrelvir for COVID-19 postexposure prophylaxis in household contacts
Ensitrelvir for COVID-19 postexposure prophylaxis in household contacts
Cefiderocol activity against multidrug-resistant isolates from the PERSEUS study: relationship between cefiderocol minimum inhibitory concentration and clinical outcomes
Cefiderocol activity against multidrug-resistant isolates from the PERSEUS study: relationship between cefiderocol minimum inhibitory concentration and clinical outcomes
MIC determinations for cefiderocol using broth microdilution can be affected by Mueller–Hinton broth manufacturer source, but not by their media lots
MIC determinations for cefiderocol using broth microdilution can be affected by Mueller–Hinton broth manufacturer source, but not by their media lots
Open-label phase 2 study of single and multiple doses of cefiderocol in hospitalised infants aged less than 3 months with suspected/confirmed aerobic Gram-negative bacterial infections
Open-label phase 2 study of single and multiple doses of cefiderocol in hospitalised infants aged less than 3 months with suspected/confirmed aerobic Gram-negative bacterial infections
All-cause mortality rates in adults with carbapenem-resistant Gram-negative bacterial infections: a comprehensive review of pathogen-focused, prospective, randomized, interventional clinical studies
All-cause mortality rates in adults with carbapenem-resistant Gram-negative bacterial infections: a comprehensive review of pathogen-focused, prospective, randomized, interventional clinical studies
Cefiderocol for injection: compatibility testing using the MINI-BAG plus container system and the VIAL-MATE adaptor
Cefiderocol for injection: compatibility testing using the MINI-BAG plus container system and the VIAL-MATE adaptor
In vitro activity of cefiderocol against U.S. and European Gram-negative clinical isolates collected in 2020 as part of the SENTRY antimicrobial surveillance program
In vitro activity of cefiderocol against U.S. and European Gram-negative clinical isolates collected in 2020 as part of the SENTRY antimicrobial surveillance program
404
Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial
Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial
Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP ): a randomised, double-blind, phase 3, non-inferiority trial
Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP ): a randomised, double-blind, phase 3, non-inferiority trial
Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial
Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial
Cefiderocol, a siderophore cephalosporin for Gram-negative bacterial infections: Pharmacokinetics and safety in subjects with renal impairment
Cefiderocol, a siderophore cephalosporin for Gram-negative bacterial infections: Pharmacokinetics and safety in subjects with renal impairment
In vitro activity of the siderophore cephalosporin, cefiderocol, against a recent collection of clinically relevant Gram-negative bacilli from North America and Europe, including carbapenem-nonsusceptible isolates (SIDERO-WT-2014 study)
In vitro activity of the siderophore cephalosporin, cefiderocol, against a recent collection of clinically relevant Gram-negative bacilli from North America and Europe, including carbapenem-nonsusceptible isolates (SIDERO-WT-2014 study)
In vitro activity of the siderophore cephalosporin, cefiderocol, against carbapenem-nonsusceptible and multidrug-resistant isolates of Gram-negative bacilli collected worldwide in 2014 to 2016
In vitro activity of the siderophore cephalosporin, cefiderocol, against carbapenem-nonsusceptible and multidrug-resistant isolates of Gram-negative bacilli collected worldwide in 2014 to 2016
Test with view block
Population pharmacokinetic analysis of cefiderocol, a parenteral siderophore cephalosporin, in healthy subjects, subjects with various degrees of renal function, and patients with complicated urinary tract infection or acute uncomplicated pyelonephritis
Population pharmacokinetic analysis of cefiderocol, a parenteral siderophore cephalosporin, in healthy subjects, subjects with various degrees of renal function, and patients with complicated urinary tract infection or acute uncomplicated pyelonephritis
Ensitrelvir for the treatment of nonhospitalized adults with COVID-19: Results from the SCORPIO-HR, phase 3, randomized, double-blind, placebo-controlled trial
Ensitrelvir for the treatment of nonhospitalized adults with COVID-19: Results from the SCORPIO-HR, phase 3, randomized, double-blind, placebo-controlled trial
Ensitrelvir for the treatment of COVID-19: Final analysis of a post-marketing surveillance from Japan
Ensitrelvir for the treatment of COVID-19: Final analysis of a post-marketing surveillance from Japan
Pharmacokinetics, safety and tolerability of single-dose or multiple-dose cefiderocol in hospitalized pediatric patients three months to less than eighteen years old with infections treated with standard-of-care antibiotics in the PEDI-CEFI phase 2 study
Pharmacokinetics, safety and tolerability of single-dose or multiple-dose cefiderocol in hospitalized pediatric patients three months to less than eighteen years old with infections treated with standard-of-care antibiotics in the PEDI-CEFI phase 2 study
In vitro activity assessment of cefiderocol against Enterobacterales, Pseudomonas aeruginosa, and Acinetobacter spp., including β-lactam nonsusceptible molecularly characterized isolates, collected from 2020 to 2021 in the United States and European hospitals
In vitro activity assessment of cefiderocol against Enterobacterales, Pseudomonas aeruginosa, and Acinetobacter spp., including β-lactam nonsusceptible molecularly characterized isolates, collected from 2020 to 2021 in the United States and European hospitals
Ensitrelvir to prevent COVID-19 in households: SCORPIO-PEP phase III placebo-controlled trial results
Ensitrelvir to prevent COVID-19 in households: SCORPIO-PEP phase III placebo-controlled trial results
Pharmacokinetics, safety, and tolerability of cefiderocol, a novel siderophore cephalosporin for Gram-negative bacteria, in healthy subjects
Pharmacokinetics, safety, and tolerability of cefiderocol, a novel siderophore cephalosporin for Gram-negative bacteria, in healthy subjects
In vitro activity of cefiderocol against European Enterobacterales, including isolates resistant to meropenem and recent β-lactam/β-lactamase inhibitor combinations
In vitro activity of cefiderocol against European Enterobacterales, including isolates resistant to meropenem and recent β-lactam/β-lactamase inhibitor combinations
In vitro activity of cefiderocol against European Pseudomonas aeruginosa and Acinetobacter spp., including isolates resistant to meropenem and recent β-lactam/β-lactamase inhibitor combinations
In vitro activity of cefiderocol against European Pseudomonas aeruginosa and Acinetobacter spp., including isolates resistant to meropenem and recent β-lactam/β-lactamase inhibitor combinations
In vitro activity of cefiderocol against Gram-negative bacteria isolated from burn patients
In vitro activity of cefiderocol against Gram-negative bacteria isolated from burn patients
In vitro activity of cefiderocol against MBL-producing Gram-negative bacteria collected in North America and Europe in five consecutive annual multinational SIDERO-WT surveillance studies (2014-2019)
In vitro activity of cefiderocol against MBL-producing Gram-negative bacteria collected in North America and Europe in five consecutive annual multinational SIDERO-WT surveillance studies (2014-2019)
Evaluation of cefiderocol trailing and other unclear susceptibility testing endpoints for Acinetobacter spp.
Evaluation of cefiderocol trailing and other unclear susceptibility testing endpoints for Acinetobacter spp.
In vitro activity of cefiderocol against highly resistant Gram-negative pathogens collected in the SENTRY Surveillance Program between 2020 and 2024
In vitro activity of cefiderocol against highly resistant Gram-negative pathogens collected in the SENTRY Surveillance Program between 2020 and 2024
Cefiderocol for the treatment of infections due to metallo-beta-lactamase-producing pathogens in the CREDIBLE-CR and APEKS-NP phase 3 randomized studies
Cefiderocol for the treatment of infections due to metallo-beta-lactamase-producing pathogens in the CREDIBLE-CR and APEKS-NP phase 3 randomized studies
In vitro susceptibility of Gram-negative pathogens to cefiderocol in five consecutive annual multinational SIDERO-WT surveillance studies, 2014 to 2019
In vitro susceptibility of Gram-negative pathogens to cefiderocol in five consecutive annual multinational SIDERO-WT surveillance studies, 2014 to 2019
Intrapulmonary pharmacokinetics of cefiderocol, a novel siderophore cephalosporin, in healthy adult subjects
Intrapulmonary pharmacokinetics of cefiderocol, a novel siderophore cephalosporin, in healthy adult subjects
Cefiderocol treatment for patients with multidrug- and carbapenem-resistant Pseudomonas aeruginosa infections in the compassionate use program
Cefiderocol treatment for patients with multidrug- and carbapenem-resistant Pseudomonas aeruginosa infections in the compassionate use program
In vitro activity of cefiderocol against meropenem-nonsusceptible Gram-negative bacilli with defined β-lactamase carriage: SIDERO-WT surveillance studies, 2014-2019
In vitro activity of cefiderocol against meropenem-nonsusceptible Gram-negative bacilli with defined β-lactamase carriage: SIDERO-WT surveillance studies, 2014-2019
Heteroresistance to cefiderocol in carbapenem-resistant Acinetobacter baumannii in the CREDIBLE-CR study was not linked to clinical outcomes: a post hoc analysis
Heteroresistance to cefiderocol in carbapenem-resistant Acinetobacter baumannii in the CREDIBLE-CR study was not linked to clinical outcomes: a post hoc analysis
Evidence for efficacy of cefiderocol against OXA-48-containing Isolates from the APEKS-NP and CREDIBLE-CR trials
Evidence for efficacy of cefiderocol against OXA-48-containing Isolates from the APEKS-NP and CREDIBLE-CR trials
Discovery of S-217622, a noncovalent oral SARS-CoV-2 3CL protease inhibitor cinical candidate for treating COVID-19
Discovery of S-217622, a noncovalent oral SARS-CoV-2 3CL protease inhibitor cinical candidate for treating COVID-19
Safety, tolerability, and pharmacokinetics of the novel antiviral agent ensitrelvir fumaric acid, a SARS-CoV-2 3CL protease inhibitor, in healthy adults
Safety, tolerability, and pharmacokinetics of the novel antiviral agent ensitrelvir fumaric acid, a SARS-CoV-2 3CL protease inhibitor, in healthy adults
A randomized phase 2/3 study of ensitrelvir, a novel Oral SARS-CoV-2 3C-like protease Inhibitor, in Japanese patients With mild-to-moderate COVID-19 or asymptomatic SARS-CoV-2 infection: Results of the phase 2a part
A randomized phase 2/3 study of ensitrelvir, a novel Oral SARS-CoV-2 3C-like protease Inhibitor, in Japanese patients With mild-to-moderate COVID-19 or asymptomatic SARS-CoV-2 infection: Results of the phase 2a part
Efficacy and safety of ensitrelvir in patients with mild-to-moderate COVID-19: the phase 2b part of a randomized, placebo-controlled, phase 2/3 study
Efficacy and safety of ensitrelvir in patients with mild-to-moderate COVID-19: the phase 2b part of a randomized, placebo-controlled, phase 2/3 study
Efficacy and safety of 5-Day oral ensitrelvir for patients with mild-to-moderate COVID-19: The SCORPIO-SR randomized clinical trial
Efficacy and safety of 5-Day oral ensitrelvir for patients with mild-to-moderate COVID-19: The SCORPIO-SR randomized clinical trial
Ensitrelvir is effective against SARS-CoV-2 3CL protease mutants circulating globally
Ensitrelvir is effective against SARS-CoV-2 3CL protease mutants circulating globally
Efficacy comparison of 3CL protease inhibitors ensitrelvir and nirmatrelvir against SARS-CoV-2 in vitro and in vivo
Efficacy comparison of 3CL protease inhibitors ensitrelvir and nirmatrelvir against SARS-CoV-2 in vitro and in vivo
Evaluation of the drug–drug interaction potential of ensitrelvir fumaric acid with Cytochrome P450 3A substrates in healthy Japanese adults
Evaluation of the drug–drug interaction potential of ensitrelvir fumaric acid with Cytochrome P450 3A substrates in healthy Japanese adults
Evaluation of drug-drug interactions of ensitrelvir, a SARS-CoV-2 3CL protease inhibitor, with transporter substrates based on in vitro and a clinical studies
Evaluation of drug-drug interactions of ensitrelvir, a SARS-CoV-2 3CL protease inhibitor, with transporter substrates based on in vitro and a clinical studies
A phase 1 study of ensitrelvir fumaric acid tablets evaluating the safety, pharmacokinetics and food effect in healthy adult populations
A phase 1 study of ensitrelvir fumaric acid tablets evaluating the safety, pharmacokinetics and food effect in healthy adult populations
Utility of coproporphyrin-I determination in first-in-human study for early evaluation of OATP1B inhibitory potential based on investigation of ensitrelvir, an oral SARS-CoV-2 3C-like protease inhibitor
Utility of coproporphyrin-I determination in first-in-human study for early evaluation of OATP1B inhibitory potential based on investigation of ensitrelvir, an oral SARS-CoV-2 3C-like protease inhibitor
The effect of renal impairment on the pharmacokinetics and safety of ensitrelvir, a SARS-CoV-2 3CL protease inhibitor
The effect of renal impairment on the pharmacokinetics and safety of ensitrelvir, a SARS-CoV-2 3CL protease inhibitor
Real-world effectiveness of ensitrelvir in reducing severe outcomes in outpatients at high risk for COVID-19
Real-world effectiveness of ensitrelvir in reducing severe outcomes in outpatients at high risk for COVID-19
Prevention of post COVID-19 condition by early treatment with ensitrelvir in the phase 3 SCORPIO-SR trial
Prevention of post COVID-19 condition by early treatment with ensitrelvir in the phase 3 SCORPIO-SR trial
Efficacy and safety of ensitrelvir for asymptomatic or mild COVID-19: An exploratory analysis of a multicenter, randomized, phase 2b/3 clinical trial
Efficacy and safety of ensitrelvir for asymptomatic or mild COVID-19: An exploratory analysis of a multicenter, randomized, phase 2b/3 clinical trial
Inhibition of phosphodiesterase-4D in adults with fragile X syndrome: a randomized, placebo-controlled, phase 2 clinical trial
Inhibition of phosphodiesterase-4D in adults with fragile X syndrome: a randomized, placebo-controlled, phase 2 clinical trial
Design and synthesis of selective phosphodiesterase 4D (PDE4D) allosteric inhibitors for the treatment of fragile X syndrome and other brain disorders
Design and synthesis of selective phosphodiesterase 4D (PDE4D) allosteric inhibitors for the treatment of fragile X syndrome and other brain disorders
Genetic association of phosphodiesterases with human cognitive performance
Genetic association of phosphodiesterases with human cognitive performance
Memory enhancing effects of BPN14770, an allosteric inhibitor of phosphodiesterase-4D, in wild-type and humanized mice
Memory enhancing effects of BPN14770, an allosteric inhibitor of phosphodiesterase-4D, in wild-type and humanized mice
Multiple behavior phenotypes of the fragile-X syndrome mouse model respond to chronic inhibition of phosphodiesterase-4D (PDE4D)
Multiple behavior phenotypes of the fragile-X syndrome mouse model respond to chronic inhibition of phosphodiesterase-4D (PDE4D)
Effectiveness and safety of cefiderocol in clinical practice for treatment of patients with Gram-Negative bacterial infections: US interim results of the PROVE Study
Effectiveness and safety of cefiderocol in clinical practice for treatment of patients with Gram-Negative bacterial infections: US interim results of the PROVE Study
Early Access Programs
Learn about early access to investigational agents outside of a clinical trial for eligible patients
Patient Assistance
Learn more about our program to help eligible, uninsured patients access our products
Investigator-Initiated Research
Find out more on how to submit a proposal for investigator-initated research
Medical Writing Grants
Find out more about how Shionogi provides medical writing grants to support the development of publications
Educational Grants
Learn how to submit a request for a Continuing Medical Education (CME) grant
Advancing Research for Patients With Fragile X Syndrome
Learn more about clinical trials for Fragile X syndrome
FETROJA® (cefiderocol) for injection, for intravenous use
Connect With Us
Our Medical Information Contact Center is available to speak with you between 9 AM and 7 PM ET, Mon-Fri
Disease State Resources
Explore disease state resources
Product Resources
Explore product resources
RADICAVA ORS® (edaravone) oral suspension
XOCOVA® (ensitrelvir) tablets, for oral use
METHYLIN® (methylphenidate HCl) oral solution, CII
Infographic
Ensitrelvir: Summary of Key Clinical Information
Report Adverse Events or Product Quality Complaint
To report suspected adverse events or product complaints, please call us at
Shionogi-Sponsored CME Program
The Plot (and Sputum) Thickens: Encountering Carbapenem Resistance in Critically Ill Patients
Pipeline
Learn more about the investigational compounds currently in our U.S. pipeline
Clinical Trials
Learn more about Shionogi clinical trials for infectious diseases, neurology/CNS, metabolic disorders, and oncology
Current impact of COVID-19 in long-term care facilities in the United States: a systematic literature review
Current impact of COVID-19 in long-term care facilities in the United States: a systematic literature review
XOCOVA® (ensitrelvir)
Fragile X Syndrome
Medical Information
Product
Prescribing Information
Submit a Medical Inquiry
Publications
Congresses
Resources
Search
Request an MSL
Home
Medical Writing Grants
Educational Grants
Disease State
Cefiderocol activity across highly resistant Pseudomonas aeruginosa ventilator-associated pneumonia isolates: a global surveillance study of SENTRY 2020-2024
Cefiderocol activity across highly resistant Pseudomonas aeruginosa ventilator-associated pneumonia isolates: a global surveillance study of SENTRY 2020-2024
Early pre-symptomatic treatment with ensitrelvir among PCR-positive, SARS-CoV-2–exposed and infected household contacts: SCORPIO-PEP subpopulation analysis
Early pre-symptomatic treatment with ensitrelvir among PCR-positive, SARS-CoV-2–exposed and infected household contacts: SCORPIO-PEP subpopulation analysis
In vitro activity of cefiderocol against a collection of infrequently isolated gram-negative bacterial isolates from the SENTRY antimicrobial surveillance program
In vitro activity of cefiderocol against a collection of infrequently isolated gram-negative bacterial isolates from the SENTRY antimicrobial surveillance program
Brain microstructural disorganization as a potential mechanism of post-COVID-19 condition and the onset-suppressive effects of ensitrelvir revealed by advanced diffusion MRI
Brain microstructural disorganization as a potential mechanism of post-COVID-19 condition and the onset-suppressive effects of ensitrelvir revealed by advanced diffusion MRI
Outcomes of cefiderocol treatment in US patients with respiratory tract infections: subgroup analysis of the PROVE observational study
Outcomes of cefiderocol treatment in US patients with respiratory tract infections: subgroup analysis of the PROVE observational study
Systematic literature review of the clinical outcomes associated with cefiderocol therapy for Stenotrophomonas maltophilia infections
Systematic literature review of the clinical outcomes associated with cefiderocol therapy for Stenotrophomonas maltophilia infections
Clinical outcomes after cefiderocol therapy for Pseudomonas spp. infections: results from a systematic literature review
Clinical outcomes after cefiderocol therapy for Pseudomonas spp. infections: results from a systematic literature review
Reduction of infectious SARS-CoV-2 and viral titer with ensitrelvir: a pooled analysis of SCORPIO-SR and SCORPIO-HR trials
Reduction of infectious SARS-CoV-2 and viral titer with ensitrelvir: a pooled analysis of SCORPIO-SR and SCORPIO-HR trials
Ensitrelvir suppresses fatigue-like symptoms derived from SARS-CoV-2 infection in hamsters
Ensitrelvir suppresses fatigue-like symptoms derived from SARS-CoV-2 infection in hamsters
Activity of cefiderocol against carbapenem-nonsusceptible gram-negative isolates from skin and soft tissue infections in US and European medical centers collected as part of the SENTRY antimicrobial surveillance program (2020–2024)
Activity of cefiderocol against carbapenem-nonsusceptible gram-negative isolates from skin and soft tissue infections in US and European medical centers collected as part of the SENTRY antimicrobial surveillance program (2020–2024)
Reproducibility of cefiderocol-xeruborbactam in cation adjusted Mueller Hinton broth (CAMHB) and iron depleted (ID) CAMHB using two reading endpoints
Reproducibility of cefiderocol-xeruborbactam in cation adjusted Mueller Hinton broth (CAMHB) and iron depleted (ID) CAMHB using two reading endpoints
Activity of cefiderocol-xeruborbactam and comparator agents against Enterobacterales, including molecularly characterized isolates recovered globally in 2024
Activity of cefiderocol-xeruborbactam and comparator agents against Enterobacterales, including molecularly characterized isolates recovered globally in 2024
Activity of cefiderocol against carbapenem-resistant Pseudomonas aeruginosa encountered in each of the different United States Census Bureau divisions
Activity of cefiderocol against carbapenem-resistant Pseudomonas aeruginosa encountered in each of the different United States Census Bureau divisions
Activity of cefiderocol against metallo-β-lactamase-carrying Pseudomonas aeruginosa of the SENTRY antimicrobial surveillance program (2020–2024)
Activity of cefiderocol against metallo-β-lactamase-carrying Pseudomonas aeruginosa of the SENTRY antimicrobial surveillance program (2020–2024)
Activity of cefiderocol-xeruborbactam and comparator agents against global Acinetobacter baumannii-calcoaceticus species complex isolates
Activity of cefiderocol-xeruborbactam and comparator agents against global Acinetobacter baumannii-calcoaceticus species complex isolates
Cefiderocol-xeruborbactam antimicrobial susceptibility testing does not require iron-depleted media
Cefiderocol-xeruborbactam antimicrobial susceptibility testing does not require iron-depleted media
Bactericidal activity of cefiderocol/xeruborbactam in a murine urinary tract infection model
Bactericidal activity of cefiderocol/xeruborbactam in a murine urinary tract infection model
Infographic
Navigating a Path for COVID‑19: Background, Management, and Prevention
Infographic
The Ongoing Threat of COVID-19
Infographic
COVID-19 May Worsen Underlying Medical Conditions
Infographic
Early Intervention in COVID-19 May Reduce Clinical Complications and Further Community Transmission
Infographic
Early Intervention After Exposure to SARS-CoV-2 Could Reduce the Likelihood of Developing COVID-19
Infographic
Shared Spaces Amid Persistent COVID-19 Risk
Shionogi-Sponsored CME Program
Mastering COVID-19 — Harnessing Post-Exposure Prophylaxis for Primary Care Excellence
Shionogi-Sponsored IME Program
The Evolving COVID-19 Landscape: Role of Post-exposure Prophylaxis
Shionogi-Sponsored CME Program
A Shield of Protection: Unmet Needs in COVID-19 Prevention and Control
Shionogi-Sponsored CME Program
The COVID Countdown: The Latest in Safeguarding Protection and Treatment for Vulnerable Populations
Shionogi-Sponsored IME Program
After Exposure, Then What? Closing the COVID-19 Prevention Gap
Liverpool COVID-19 Drug Interactions
CDC COVID Data Tracker
CDC COVID Variant Update
WHO COVID-19 Global Dashboard
COVID-19
Smartphone application-mediated, supervised, at-home telespirometry identifies statistically significant differences in erect and supine slow vital capacity and ALSFRS-R decline as a function of non-invasive ventilation treatment status in multicenter, prospective, longitudinal, observational clinical study [NCT05106569]
Smartphone application-mediated, supervised, at-home telespirometry identifies statistically significant differences in erect and supine slow vital capacity and ALSFRS-R decline as a function of non-invasive ventilation treatment status in multicenter, prospective, longitudinal, observational clinical study [NCT05106569]
Five-year trend analysis of carbapenem-resistant Enterobacterales, including isolates carrying metallo-β-lactamase genes in United States, Europe and adjacent regions during 2020–2024
Five-year trend analysis of carbapenem-resistant Enterobacterales, including isolates carrying metallo-β-lactamase genes in United States, Europe and adjacent regions during 2020–2024
COVID-19 exposure, treatment patterns, and healthcare utilization in US long-term care: retrospective EHR study
COVID-19 exposure, treatment patterns, and healthcare utilization in US long-term care: retrospective EHR study
New onset conditions, exacerbations and worsening of underlying conditions following COVID-19 infection
New onset conditions, exacerbations and worsening of underlying conditions following COVID-19 infection
Activity of cefiderocol-xeruborbactam and comparator agents against Pseudomonas aeruginosa, including molecularly characterized isolates recovered globally in 2024
Activity of cefiderocol-xeruborbactam and comparator agents against Pseudomonas aeruginosa, including molecularly characterized isolates recovered globally in 2024
Impact of acute COVID-19 on underlying chronic conditions: systematic literature review
Impact of acute COVID-19 on underlying chronic conditions: systematic literature review
Current impact of COVID-19 in long-term care facilities in the United States: systematic literature review
Current impact of COVID-19 in long-term care facilities in the United States: systematic literature review
Ceftolozane/tazobactam (C/T) and ceftazidime/avibactam (CZA) non-susceptibility (NS) among hospitalized adults with Pseudomonas aeruginosa (PSA) isolated from lower respiratory tract (LRT) clinical cultures: index and subsequent episodes in the Kaiser Permanente Southern California (KPSC) system
Ceftolozane/tazobactam (C/T) and ceftazidime/avibactam (CZA) non-susceptibility (NS) among hospitalized adults with Pseudomonas aeruginosa (PSA) isolated from lower respiratory tract (LRT) clinical cultures: index and subsequent episodes in the Kaiser Permanente Southern California (KPSC) system
Gram-negative Infections
Infographic
Cefiderocol Disk Diffusion Reading Guide
How to read zone of inhibition results
Resistant Isolate Program
Shionogi offers a laboratory testing program for isolates that are identified as non-susceptible to cefiderocol
Cefiderocol QC Isolates
Approved cefiderocol MIC and zone ranges
Cefiderocol Microbiology Resource Center
A centralized hub for information on cefiderocol susceptibility testing and surveillance
Disk Reading Guide for Cefiderocol Verification Using LSI Isolates
Cefiderocol MIC and zone results for both susceptible and non-susceptible Gram-negative isolates
Zone of Inhibition Results for LSI Cefiderocol Verification Set of Isolates
Summary of disk diffusion results for Gram-negative isolates in the LSI method verification isolate set
MIC Results of LSI Cefiderocol Verification Set of Isolates
Summary of broth microdilution results for Gram-negative isolates in the LSI method verification isolate set
CLSI M52 Document
Verification of commercial microbial identification and antimicrobial susceptibility testing systems
LSI Verification Isolates
Panel for cefiderocol available at no cost to laboratories. Visit the link below, email info@labspec.org, or call (440) 835-4458 to order
CDC Verification Isolates
Panel of isolates for laboratories to perform verification. View resource for a detailed listing of isolates and to order the panel
Infographic
PERSEUS Infographic
Real-world study on cefiderocol in critically ill patients with resistant Gram-negative pathogens
Infographic
Spectrum of Activity of Contemporary Antibiotics Against Resistant Gram-Negative Pathogens
Educational resource
Infographic
Difficult-to-Treat P. aeruginosa: In Vitro Insights on BL-BLI Cross-Resistance from the SENTRY Program
In vitro study summary
Video
Cefiderocol Disk Diffusion Instructional Video
Instructional video on how to read zone of inhibition results
Infographic
Summary of Stenotrophomonas, Achromobacter, and Burkholderia Infections in the PERSEUS Study
Clinical Study Summary
FETROJA® (cefiderocol)
Antimicrobial Susceptibility Testing Resource
The latest information related to cefiderocol antimicrobial susceptibility testing
Association of edaravone with improved progression-free survival in patients with amyotrophic lateral sclerosis: a propensity score–matched analysis of the optum claims database
Association of edaravone with improved progression-free survival in patients with amyotrophic lateral sclerosis: a propensity score–matched analysis of the optum claims database
Association of edaravone treatment with slower functional decline in a real-world cohort of patients with amyotrophic lateral sclerosis with elevated neurofilament light chain
Association of edaravone treatment with slower functional decline in a real-world cohort of patients with amyotrophic lateral sclerosis with elevated neurofilament light chain
The effect of edaravone on corticospinal hyperexcitability (CSHE) in ALS and the utility of SICI as a pharmacodynamic biomarker
The effect of edaravone on corticospinal hyperexcitability (CSHE) in ALS and the utility of SICI as a pharmacodynamic biomarker
At-home telespirometry identifies baseline erect slow vital capacity (eSVC) at ≤80%-predicted as a pivotal benchmark separating rapid from less rapid decline in eSVC, supine SVC, and amyotrophic lateral sclerosis functional rating scale-revised score in observational study (NCT05106569)
At-home telespirometry identifies baseline erect slow vital capacity (eSVC) at ≤80%-predicted as a pivotal benchmark separating rapid from less rapid decline in eSVC, supine SVC, and amyotrophic lateral sclerosis functional rating scale-revised score in observational study (NCT05106569)
Cefiderocol Breakpoints
Approved breakpoints for cefiderocol susceptibility testing
Infographic
Preparation of Iron-Depleted Cation-Adjusted Mueller Hinton Broth
Infographic on ID-CAMHB recipe
Video
Preparation of Iron-Depleted Cation-Adjusted Mueller Hinton Broth Instructional Video
Instructional video on ID-CAMHB recipe
Video
Cefiderocol Broth Microdilution Reading Guidance Instructional Video
Determination of cefiderocol MIC values using the broth microdilution method
Fetroja - Administration via a Midline Catheter
Fetroja - Temperature Excursion Parameters for Unreconstituted Powder in Vials Lot Number 0052
Fetroja - Temperature Excursion Parameters for Unreconstituted Powder in Vials Lot Number 0051
Fetroja - Temperature Excursion Parameters for Unreconstituted Powder in Vials Lot Number 0050
Fetroja - Temperature Excursion Parameters for Unreconstituted Powder in Vials Lot Number 0049
Fetroja - Maximum Concentration and Range of Volume of Diluted Infusion Solution
Fetroja - Preparation of Doses Using Sterile Water
Fetroja - Infusion Therapy Providers and Outpatient Cefiderocol Administration
Fetroja - Temperature Excursion Parameters for Unreconstituted Powder in Vials Lot Number 0048
Fetroja - Temperature Excursion Parameters for Unreconstituted Powder in Vials Lot Number 0047
Fetroja - Temperature Excursion Parameters for Unreconstituted Powder in Vials Lot Number 0046
Fetroja - Temperature Excursion Parameters for Unreconstituted Powder in Vials Lot Number 0045
Fetroja - Temperature Excursion Parameters for Unreconstituted Powder in Vials Lot Number 0044
Fetroja - pH, Osmolarity, and Osmolality
Fetroja - The GAME CHANGER Trial
Fetroja - Temperature Excursion Parameters for Unreconstituted Powder in Vials Lot Number 0043
Fetroja - Temperature Excursion Parameters for Unreconstituted Powder in Vials Lot Number 0042
Fetroja - Temperature Excursion Parameters for Unreconstituted Powder in Vials Lot Number 0041
Fetroja - Temperature Excursion Parameters for Unreconstituted Powder in Vials Lot Number 0040
Fetroja - Use with Elastomeric Devices
Fetroja - Postmarketing Development of Non-Susceptibility in Patients
Fetroja - Density of Reconstituted Vial
Fetroja_Compatibility with IV Bag Materials
Fetroja - Temperature Excursion Parameters for Unreconstituted Powder in Vials Lot Number 0039
Fetroja - Temperature Excursion Parameters for Unreconstituted Powder in Vials Lot Number 0038
Fetroja - Temperature Excursion Parameters for Unreconstituted Powder in Vials Lot Number 0037
Fetroja - Use in Patients with Hypersensitivity or Cross-Sensitivity to Beta-Lactam Antibiotics
Fetroja - Development of Non-Susceptibility in the Clinical Development Program
Fetroja - Temperature Excursion Parameters for Unreconstituted Powder in Vials Lot Number 0035
Fetroja_Shelf Life
Fetroja - Temperature Excursion Parameters for Unreconstituted Powder in Vials Lot Number 0034
Fetroja - Comparison to Sulbactam-Durlobactam
Fetroja - Temperature Excursion Parameters for Unreconstituted Powder in Vials Lot Number 0033
Fetroja - Temperature Excursion Parameters for Unreconstituted Powder in Vials Lot Number 0032
Fetroja - Temperature Excursion Parameters for Unreconstituted Powder in Vials Lot Number 0031
Fetroja - Temperature Excursion Parameters for Unreconstituted Powder in Vials Lot Number 0030
Fetroja - Temperature Excursion Parameters for Unreconstituted Powder in Vials Lot Number 0029
Fetroja - Temperature Excursion Parameters for Unreconstituted Powder in Vials Lot Number 0028
Fetroja - Dosing Outpatient Use-Home Infusion
Fetroja - Temperature Excursion Parameters for Unreconstituted Powder in Vials Lot Number 0026
Fetroja - Skin Penetration-Use In Skin Infections and Wounds
Fetroja - Y-Site Compatibility
Fetroja - Temperature Excursion Parameters for Unreconstituted Powder in Vials Lot Number 0024
Fetroja - Effect on Iron Homeostasis and Red Blood Cell Parameters
Fetroja - Activity Against Stenotrophomonas
Fetroja - Activity vs Resistant Acinetobacter spp
Fetroja - Beyond-Use Date with Mini-Bag Plus and Vial-Mate Adaptors
Fetroja - Activity Against Resistant Pseudomonas aeruginosa
Fetroja - Mortality in Phase 2 and Phase 3 Clinical Studies
Cefiderocol Early Access Program
Fetroja - Use in Intraabdominal Infections
Fetroja - Breakpoints
Fetroja - Compatibility with Mini-Bags and Vial-Mate Adaptor
Fetroja - Use in Patients with Renal Impairment or Augmented Renal Clearance
Fetroja - Use in Patients with Altered Iron Homeostasis
Fetroja - Use in Pediatric Patients
Fetroja - Bone Penetration & Use in Osteomyelitis-Bone-Joint Infections
Fetroja - Continuous Infusion and Extended Stability
Fetroja - CREDIBLE-CR
Fetroja - Administration Less Than 3 Hours
Fetroja – Availability of Antimicrobial Susceptibility Testing (AST) Resources
Fetroja - PROVE (Real-World Evidence) Study
Xocova - Mechanism of Action
Xocova - Clinical Trials Program
Fetroja - Temperature Excursion Parameters for Unreconstituted Powder in Vials Lot Number 0054
Fetroja - Temperature Excursion Parameters for Unreconstituted Powder in Vials Lot Number 0053
Fetroja - Temperature Excursion Parameters for Unreconstituted Powder in Vials Lot Number 0055
Fetroja - Temperature Excursion Parameters for Unreconstituted Powder in Vials Lot Number 0056
Fetroja - Temperature Excursion Parameters for Unreconstituted Powder in Vials Lot Number 0057
Fetroja - Comparison to Aztreonam-Avibactam (including Aztreonam-Avycaz)
Fetroja - Temperature Excursion Parameters for Unreconstituted Powder in Vials Lot Number 0059
Fetroja - Temperature Excursion Parameters for Unreconstituted Powder in Vials Lot Number 0058
Fetroja - Resistant Isolate Program
Fetroja - Real-World Evidence
Fetroja - PERSEUS (Real World Evidence) Study
Fetroja - Temperature Excursion Parameters for Unreconstituted Powder in Vials Lot Number 0061
Fetroja - Temperature Excursion Parameters for Unreconstituted Powder in Vials Lot Number 0060
Fetroja - Temperature Excursion Parameters for Unreconstituted Powder in Vials Lot Number 0062
Fetroja - Stability During Pneumatic Tube Transport
Fetroja - Temperature Excursion Parameters for Unreconstituted Powder in Vials Lot Number 0070
Fetroja - Temperature Excursion Parameters for Unreconstituted Powder in Vials Lot Number 0067
Fetroja - Temperature Excursion Parameters for Unreconstituted Powder in Vials Lot Number 0066
Fetroja - Temperature Excursion Parameters for Unreconstituted Powder in Vials Lot Number 0068
Fetroja - Cross-Resistance to Other Antibiotics
Fetroja - Temperature Excursion Parameters for Unreconstituted Powder in Vials Lot Number 0069
Fetroja - Temperature Excursion Parameters for Unreconstituted Powder in Vials Lot Number 0072
Fetroja - Temperature Excursion Parameters for Unreconstituted Powder in Vials Lot Number 0071
Fetroja - Temperature Excursion Parameters for Unreconstituted Powder in Vials Lot Number 0073
Fetroja - Temperature Excursion Parameters for Unreconstituted Powder in Vials Lot Number 0075
Fetroja - Temperature Excursion Parameters for Unreconstituted Powder in Vials Lot Number 0074
Fetroja - Eosinophilia
Fetroja - Temperature Excursion Parameters for Unreconstituted Powder in Vials Lot Number 0077
Fetroja - Temperature Excursion Parameters for Unreconstituted Powder in Vials Lot Number 0076
Fetroja - Temperature Excursion Parameters for Unreconstituted Powder in Vials Lot Number 0078
Fetroja - Temperature Excursion Parameters for Unreconstituted Powder in Vials Lot Number 0079
Xocova - Phase 2 and 3 (SCORPIO-SR) Studies
Xocova - Use Beyond 5 Days
Xocova – Resistance
Xocova - Real World Evidence
Xocova - Use in Hepatic Impairment
Xocova - Effect of Food on Pharmacokinetics
Xocova - Storage, Stability, and Shelf Life
Xocova - Dosage and Administration
Xocova - Gluten Content
Xocova - Animal Products
Xocova - Latex Content
Xocova - Kosher Status
Xocova - Dairy Content
Xocova - Pre-Exposure Prophylaxis
Xocova - Use in Post-Exposure Prophylaxis
Xocova - SCORPIO-HR
Xocova - Incidence of Dysgeusia related to Ensitrelvir (Safety)
Xocova - Prevention of Long-COVID-19
Xocova - Drug-Drug Interactions
Xocova - Isolation, Quarantine, Masking, and
Personal Protective Equipment (PPE) Considerations
Personal Protective Equipment (PPE) Considerations
Xocova - Product Availability for Patients
Xocova - Availability of Product
Xocova - Use in Pregnancy and Lactation
Xocova - Use Following Positivity or Development of
Symptoms During Post-Exposure Prophylaxis
Symptoms During Post-Exposure Prophylaxis
Xocova - Use in Treatment
Xocova - Use in Immunocompromised Patients
Xocova - Use in Renal Impairment
Xocova - Use with Cardiovascular Drugs
Xocova - Use with Antiplatelets
Xocova - Use with Anticoagulants
Xocova - Use with Immunosuppressants
Xocova - Incidence of Rebound
Xocova - Use in a Geriatric Population
Xocova - Incidence of Liver Abnormalities
Fetroja - Photostability
Xocova - Effect on SARS-CoV-2 Transmission
Fetroja - Temperature Excursion Parameters for Unreconstituted Powder in Vials Lot Number 0083
Fetroja - Temperature Excursion Parameters for Unreconstituted Powder in Vials Lot Number 0082
Fetroja - Temperature Excursion Parameters for Unreconstituted Powder in Vials Lot Number 0081
Fetroja - Temperature Excursion Parameters for Unreconstituted Powder in Vials Lot Number 0080
Xocova - Pharmacokinetics
Xocova - Incidence of Allergic Reactions (Hypersensitivity)
Fetroja - Temperature Excursion Parameters for Unreconstituted Powder in Vials Lot Number 0085
Fetroja - Temperature Excursion Parameters for Unreconstituted Powder in Vials Lot Number 0084